Alcoholic steatohepatitis: Management and prognosis

被引:9
作者
Maher J.J. [1 ]
机构
[1] Rice Liver Center Laboratory, San Francisco General Hospital, San Francisco, CA 94110
关键词
International Normalize Ratio; Pentoxifylline; Alcoholic Liver Disease; Alcoholic Hepatitis; Severe Alcoholic Hepatitis;
D O I
10.1007/s11894-008-0019-6
中图分类号
学科分类号
摘要
Alcoholic hepatitis is a disease with a wide range of severity. Patients with severe disease have short-term mortality rates above 35%. In these high-risk patients, pharmacologic therapy is an important adjunct to supportive medical care and has been proved to improve survival. Given the benefit of drug treatment, it is important to identify patients at risk of early mortality from alcoholic hepatitis. A number of validated scoring systems are useful for this purpose, including the Maddrey Discriminant Function, the Model of End-Stage Liver Disease score, and the Glasgow Alcoholic Hepatitis score. Patients judged by one or more of these criteria to have severe alcoholic hepatitis should be treated with corticosteroids or pentoxifyfline, provided they have no contraindications for this treatment. Adequate nutrition is also critical and should be provided by tube feeding if necessary. A prompt decline in serum bilirubin indicates a favorable response to therapy. Patients who do not exhibit a reduction in serum bilirubin within 1 week are considered nonresponders and have a 6-month mortality rate of 50% or higher. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:39 / 46
页数:7
相关论文
共 43 条
[1]
Mathurin P., Duchatelle V., Ramond M.J., Et al., Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone, Gastroenterology, 110, pp. 1847-1853, (1996)
[2]
Ramond M.J., Poynard T., Rueff B., Et al., A randomized trial of prednisolone in patients with severe alcoholic hepatitis, N Engl J Med, 326, pp. 507-512, (1992)
[3]
Thabut D., Naveau S., Charlotte F., Et al., The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease, J Hepatol, 44, pp. 1175-1185, (2006)
[4]
Goldberg S., Mendenhall C., Anderson S., Et al., The significance of clinically mild alcoholic hepatitis - Describing the population with minimal hyperbilirubinemia, Am J Gastroenterol, 81, pp. 1029-1034, (1986)
[5]
Maddrey W.C., Boitnott J.K., Bedine M.S., Et al., Corticosteroid therapy of alcoholic hepatitis, Gastroenterology, 75, pp. 193-199, (1978)
[6]
Carithers Jr. R.L., Herlong H.F., Diehl A.M., Et al., Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial, Ann Intern Med, 110, pp. 685-690, (1989)
[7]
Akriviadis E., Botla R., Briggs W., Et al., Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial, Gastroenterology, 119, pp. 1637-1648, (2000)
[8]
Forrest E.H., Evans C.D., Stewart S., Et al., Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow Alcoholic Hepatitis Score, Gut, 54, pp. 1174-1179, (2005)
[9]
Dunn W., Jamil L.H., Brown L.S., Et al., MELD accurately predicts mortality in patients with alcoholic hepatitis, Hepatology, 41, pp. 353-358, (2005)
[10]
Kulkarni K., Tran T., Medrano M., Et al., The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis, J Clin Gastroenterol, 38, pp. 453-459, (2004)